RapidTest.AI is positioned at the intersection of three rapidly expanding global markets: diagnostics, artificial intelligence, and at-home testing.
Initial Focus: Colorectal Cancer (CRC) Screening
A critical need with a clear path to market adoption and immediate impact.
The Challenge & Our Impact
Colorectal cancer is a leading cause of cancer-related deaths, with 1.9 million cases and 930,000 deaths in 2020 alone. Early detection through Fecal Occult Blood (FOB) tests is crucial for improving patient outcomes.
Current FOB tests are inconvenient and costly for Health Maintenance Organizations (HMOs). RapidTest.AI enables comfortable at-home testing and dramatically reduces these costs, creating a clear value proposition.
USA Market Need
Screening age lowered to 45, expanding the target population to approximately 114 million individuals.
European Market Need
Europe's Beating Cancer Plan aims to screen 90% of individuals aged 50-75, covering around 132 million people.
CRC Screening Market Size
Our addressable market for CRC testing alone presents a significant, immediate opportunity.
SOM (Israel)
$15-21M
Annual potential based on 3 million tests per year.
SAM (USA & Europe)
$1.2-1.7B
Annual potential targeting screening populations in key Western countries.
TAM (Global)
Multi-Billion
Includes other self-tests and expansion into additional global markets.
Fueling Growth in Expanding Markets
The tailwinds are strong for innovative diagnostic solutions that integrate seamlessly into the digital health ecosystem.
Global IVD Market
$217.8B
by 2031
Projected growth at a 7.8% CAGR from $102B in 2021.
AI in Healthcare Market
$503.4B
by 2034
Explosive growth at a 31.5% CAGR from $20.9B in 2023.
At-Home Testing Market
$55.5B
by 2033
Consistent growth at a 6.8% CAGR from $28.6B in 2023.